No More Daily Pills: What You Need to Know About Long-Acting Injectable PrEP

For years, PrEP has meant one thing: a daily pill, taken at roughly the same time, every single day, indefinitely. For a lot of people, that's simply not realistic — life gets busy, routines change, travel disrupts schedules, and even one or two missed doses a week can meaningfully lower how protected you actually are.

That's no longer the only option. Two FDA-approved injectable medications — Apretude and Yeztugo — now offer HIV prevention without the daily pill, and if you're a good candidate, switching may be one of the simplest changes you make for your long-term health.

Why Injectable PrEP Exists

Oral PrEP works extremely well — but only when taken consistently. In real-world use, adherence is the biggest weak point: it's not that the pill fails, it's that people don't always take it as directed. Injectable PrEP was developed specifically to remove that daily burden. Instead of remembering a pill 365 days a year, you receive an injection from your doctor on a set schedule and you're covered in between.

Apretude (Cabotegravir)

Apretude was the first injectable PrEP option approved, and it's given as an intramuscular injection every two months. Most people start with two initial injections spaced one month apart, then continue on the every-other-month schedule after that. Some people also have the option to try oral cabotegravir pills for a short trial period first, just to see how the medication feels before committing to injections.

Clinical trial data comparing cabotegravir directly to daily oral PrEP found a striking result: the risk of acquiring HIV was 88% lower in the group receiving the injection. That's not because the medication is inherently more potent — it's because removing the daily pill removed the most common point of failure. Side effects are generally mild, with soreness or tenderness at the injection site being the most frequently reported, and it tends to lessen with each subsequent dose.

Yeztugo (Lenacapavir)

Yeztugo is the newer option, approved in 2025, and it takes the "less frequent" idea even further: after an initiation regimen (a combination of oral tablets and injections), ongoing protection requires an injection just twice a year — once every six months.

In its pivotal trials, lenacapavir performed exceptionally well: one trial recorded zero infections among participants, and both studies were stopped early because the results were so clearly superior to daily oral PrEP that continuing to compare them was considered unnecessary. The most common side effects reported were injection-site reactions, headache, and nausea.

One important safety note: because Yeztugo is long-acting, it's essential to confirm an HIV-negative status before every injection. If someone were to acquire HIV while on the medication without it being caught early, there's a risk of the virus developing resistance — which is exactly why ongoing monitoring with a doctor matters, not just the injection itself.

Who Might Be a Good Fit

Injectable PrEP tends to be a strong option for people who:

• Struggle with taking a daily pill consistently, or find the daily reminder stressful or stigmatizing

• Travel frequently or have unpredictable schedules that make a daily routine difficult

• Want fewer touchpoints with their medication overall — six visits a year (or fewer) instead of managing a bottle every month

• Are already on oral PrEP and doing well, but would simply prefer a lower-maintenance option

It's not automatically the right choice for everyone — some people genuinely prefer the control and immediacy of a daily pill, and that's a completely valid choice too. The point isn't that injectable is "better" for everyone; it's that more people now have an option that actually fits how they live. This is one piece of a broader sexual health and HIV prevention program, which also includes Doxy-PEP and regular STI screening as part of a complete prevention strategy.

What Switching Actually Looks Like

Moving from oral PrEP to an injectable option isn't complicated, but it does require a doctor who can manage the transition properly: confirming your HIV status before starting, choosing the right medication for your situation, and keeping you on schedule for follow-up injections and testing.

This is exactly the kind of care that gets rushed — or missed entirely — in a traditional 10-minute appointment squeezed between an insurance-driven schedule. At U Care MD, I administer both Apretude and Yeztugo injections directly, and because visits aren't limited by insurance billing constraints, follow-up monitoring happens on the schedule that actually keeps you protected, not the schedule that's convenient for a billing code. This is the same direct primary care model that shapes every visit here — unhurried, unrushed, and built around you.

Ready to Talk About It?

If daily pills haven't been working for you, or you're simply curious whether an injectable option makes sense for your life, that's exactly the kind of conversation direct primary care is built for — unhurried, without judgment, and with a doctor who can walk you through the details start to finish.

Book a visit with U Care MD to find out if switching is the right move for you.

Frequently Asked Questions

Is injectable PrEP more effective than the daily pill? In clinical trials, injectable options outperformed daily oral PrEP — largely because they remove the risk of missed doses, which is the most common reason oral PrEP fails to fully protect someone.

How often do I need an injection? Apretude is given every two months after an initial start-up phase. Yeztugo is given twice a year, after an initiation regimen of tablets and injections.

Does the injection hurt? The most common side effect is mild soreness at the injection site, which tends to decrease with repeated doses — similar to a typical vaccine.

Can I switch from oral PrEP to an injectable option? Yes. Switching is a straightforward conversation with your doctor and does not require restarting your HIV prevention plan from scratch.

This content is educational and general in nature. HIV prevention decisions are personal and depend on individual risk factors and health history — always ready to walk through what's right for you and to help find the appropriate support if you're navigating an HIV-related risk situation.